Organovo Holdings, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended June 30, 2022; comparable period is the three months ended June 30, 2021. The filing identifies the issuer as Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc.
Business context
Organovo is an early-stage biotechnology company developing 3D human tissue models, initially focused on inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. It aims to use these models to identify drug targets and advance potential therapeutics. The company reports no meaningful revenue expected in the foreseeable future.
Financial performance and position
| Metric | Quarter ended June 30, 2022 | Quarter ended June 30, 2021 |
|---|---|---|
| Revenue | No revenue line reported; no BICO royalty revenue recorded | Not clearly stated in the presented comparison |
| Research and development expense | $1.02 million | $0.58 million |
| Selling, general and administrative expense | $2.22 million | $1.98 million |
| Total operating expense / operating loss | $3.24 million | $2.56 million |
| Net loss | $3.22 million ($0.37 per share) | $2.53 million ($0.29 per share) |
| Net cash used in operating activities | $2.41 million | $1.41 million |
Margins are not meaningful given the absence of reported quarterly revenue. At June 30, 2022, the company had cash and cash equivalents of $15.57 million, short-term investments of $9.90 million, equity securities of $0.72 million, and restricted cash of $0.14 million. Current assets were $26.91 million and current liabilities $1.28 million, for working capital of $25.63 million. Total liabilities were $2.89 million, primarily lease liabilities; the filing reports no debt balance. Accumulated deficit was $310.95 million.
Changes and cash use
- R&D expense increased 76% year over year, which management attributed mainly to increased headcount and research activity; average R&D staffing rose from five to fourteen.
- SG&A expense rose 12%, reflecting higher staffing and operating costs, partly offset by lower general corporate costs.
- Operating cash use increased by approximately $1.00 million year over year, primarily due to higher R&D activity.
- Cash, cash equivalents, and restricted cash fell $13.11 million during the quarter. Investing cash outflow included $9.89 million of Treasury-bill purchases and $0.73 million of equity-security purchases; these investment purchases are not equivalent to operating burn.
Outlook, risks, and unusual items
- Management expects fiscal 2023 operating expenses of $10 million to $12 million and believes available resources can fund operations for at least 12 months. It also says additional capital will be needed to implement its longer-term development plan.
- The company had no committed external funding. Additional financing may be unavailable or dilutive; management warns that inadequate funding could require curtailing operations or relinquishing technology rights.
- A February 2022 settlement with BICO Group included a $1.5 million nonrefundable license fee recognized in the prior quarter. No royalties were recognized this quarter because BICO had not provided timely, complete sales reports and the variable consideration was constrained.
- Management estimated a 0% probability of achieving the performance condition on certain executive options; no expense had been recorded for those awards as of June 30, 2022.
- Risks include an unproven drug-discovery strategy, continued losses, dependence on reliable human-cell supplies, need for partners and capital, clinical and regulatory uncertainty, patent challenges, COVID-19-related disruption, and potential conflicts of interest involving Viscient Biosciences.
- No loss-contingency accrual was recorded for legal matters. The BICO patent disputes were settled; the filing says other legal outcomes remain uncertain. Management assessed disclosure controls as effective and reported no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm issuer and reporting-period details: this filing is for Organovo Holdings, Inc. for the quarter ended June 30, 2022, despite the request metadata naming Vivosim Labs.
- Monitor cash burn against the stated 12-month runway and fiscal 2023 expense forecast, including the timing and terms of any future financing.
- Track progress toward validated drug targets and partnerships; the filing reports no drug candidates identified under the current strategy.
- Seek updates on BICO royalty reporting and whether royalty revenue can be reliably measured and collected.
- Assess potential dilution: approximately $28.3 million remained available under the ATM program, and the filing reports 11.40 million shares outstanding or potentially issuable on a fully diluted/reserved basis.